<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605811</url>
  </required_header>
  <id_info>
    <org_study_id>GACA1501</org_study_id>
    <nct_id>NCT02605811</nct_id>
  </id_info>
  <brief_title>Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer</brief_title>
  <official_title>Radiation Versus Temozolomide in Preventing Brain Metastases in Limited Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the response of temozolomide versus prophylactic cranial radiotherapy in
      preventing brain metastases in completed or partial remission limited small cell lung cancer
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We'd like to investigate the 2-year incidence rate of brain metastases in completed or
      partial remission limited small cell lung cancer patients who received temozolomide only for
      12 months or 25-30Gy prophylactic cranial radiotherapy in preventing brain metastases.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year incidence of brain metastases</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">426</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Metastatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>temozolomide oral 150mg/m2 d1-5/28d for 12 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prophylaxis cranial radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prophylaxis cranial radiotherapy,25-30Gy/10Fra</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>temozolomide</arm_group_label>
    <other_name>Temozolomide Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>prophylaxis cranial radiotherapy</intervention_name>
    <description>2</description>
    <arm_group_label>prophylaxis cranial radiotherapy</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological or cytological diagnosis of small-cll lung cancer histology

          2. 18 years or older

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status no more than 2

          4. Local stage SCLC without distant metastases

          5. After 1st-line chemotherapy (EP or IP) at least 4 cycles

          6. After radical radiotherapy for primary tumor and lymph node drainage area:including
             concurrent or sequence chemoradiotherapy

          7. CR or PR assessment by RECIST(1.0) before randomized

          8. Haemoglobin 10.0 g/dl, Absolute neutrophil count (ANC) 1.5^9/L, platelets 100 x 10^9/L

          9. Total bilirubin 1.5 x upper limit of normal (ULN) alanine aminotransferase (ALT) and
             aspartate aminotransferase (AST) &lt; 2.5 x ULN in the absence of liver metastases, or &lt;
             5 x ULN in case of liver metastases

         10. Creatinine clearance 60ml/min (calculated according to Cockcroft-gault formula)

        Exclusion Criteria:

          1. Mixed non-small cell lung cancer histology

          2. Neck and supraclavicular lymph node metastasis

          3. Be allergic to temozolomide or intolerable to radiotherapy

          4. Any unstable systemic disease

          5. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hailing Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>the first affiliated hospital of Guangzhou MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The first affiliated hospital of Guangzhou MC</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Haihong Yang, MD, Pricipal investigator</investigator_full_name>
    <investigator_title>Associate Chief Physician</investigator_title>
  </responsible_party>
  <keyword>limited small cell lung cancer</keyword>
  <keyword>brain metastases</keyword>
  <keyword>prophylactic cranial radiotherapy</keyword>
  <keyword>temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

